Five things to watch in markets in the week ahead
- Information about a partnership between StoneX Financial Europe GmbH and Expana
- Details about launching OTC dairy derivatives
- Quotes from executives
- Company background information
This appears to be a legitimate business announcement with sufficient factual content to create a news article. I’ll proceed with writing the article according to the guidelines.
StoneX partners with Expana to launch OTC dairy derivatives
HAMBURG - StoneX Financial Europe GmbH, a subsidiary of StoneX Group Inc. (NASDAQ:SNEX), announced Tuesday a collaboration with Expana to introduce over-the-counter dairy derivatives based on Expana’s IOSCO-assured European Union dairy benchmarks. StoneX, currently trading near $99 per share, has demonstrated remarkable performance with a 78.4% return over the past year. According to InvestingPro analysis, the company maintains a "Good" financial health score, reflecting its strong market position.
The new derivatives will initially cover fat-filled milk powder and high-protein whey, with plans to expand to additional dairy products in the future. The partnership aims to enhance price transparency and expand risk management tools available to the global dairy industry. This expansion aligns with StoneX’s impressive growth trajectory, as evidenced by its substantial revenue of $129.4 billion in the last twelve months.
Users of StoneX Plus will gain direct access to Expana’s benchmarks within their trading workflow, allowing market participants to make more informed hedging and risk management decisions.
"Our clients in the global dairy sector are increasingly looking for new ways to manage risk and respond to market volatility," said Liam Fenton, Global Head of Dairy & Food Group at StoneX, according to the press release.
Spencer Wicks, CEO of Expana, described the collaboration as "a major milestone for the dairy industry," noting that it combines Expana’s independent benchmarks with StoneX’s experience in OTC and futures dairy markets.
The initiative is designed to improve liquidity and support more transparent pricing across the dairy industry, according to the companies.
StoneX Group Inc., a Fortune 50 company headquartered in New York City, serves over 54,000 commercial, institutional, and payments clients worldwide. Expana specializes in agrifood-focused price reporting and market intelligence. As a prominent player in the Capital Markets industry, StoneX currently appears slightly overvalued according to InvestingPro Fair Value metrics. Discover more insights about StoneX and other market leaders through InvestingPro’s comprehensive research reports, available for over 1,400 US stocks.
In other recent news, StoneX Group Inc. reported its third-quarter earnings for 2025, showing mixed results. The company posted an earnings per share of $1.22, which was below the forecasted $1.41, resulting in a 13.48% negative surprise. However, StoneX Group exceeded revenue expectations, reporting $1.024 billion compared to the anticipated $927.85 million, marking a 9.93% positive surprise. Additionally, StoneX Group has filed a prospectus supplement to register the potential resale of up to 3.1 million shares of its common stock by certain selling stockholders, although the company will not receive any proceeds from these sales.
In other developments, StoneX Group’s board of directors has authorized a new stock repurchase program for fiscal year 2026. This program allows for the repurchase of up to 2.25 million shares of its outstanding common stock, commencing on October 1, 2025, and concluding on September 30, 2026. The repurchases can occur through open market transactions or private deals, with the timing and amount at the discretion of senior management. These recent developments highlight ongoing strategic financial maneuvers by StoneX Group.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.